Galapagos NV (NASDAQ:GLPG) Q4 2022 Earnings Conference Call February 24, 2023 8:00 AM ET

Company Participants

Sofie Van Gijsel - Senior Director of Investor Relations

Paul Stoffels - Chief Executive Officer

Bart Filius - Chief Operating Officer & President

Daniele D’Ambrosio - Head of Immunology

Michele Manto - Chief Commercial Officer

Conference Call Participants

Phil Nadeau - Cowen

Peter Verdult - Citi

Brian Abrahams - RBC Capital Markets

Rosie Turner - Jefferies

Dane Leone - Raymond James

Suzanne van Voorthuizen - Kempen

Operator

Good day and thank you for standing by. Welcome to the Galapagos Full Year 2022 Financial Results Call and Webcast. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions] Please note that today's conference is being recorded.

I would now like to hand over to your first speaker Sofie Van Gijsel. Please, go ahead.

Sofie Van Gijsel

Thank you and welcome to the audio webcast of Galapagos full year 2022 results. I'm Sofie Van Gijsel, Investor Relations, representing the reporting team at Galapagos. This recorded webcast is accessible via the Galapagos website homepage and will be available for downloads and replays later on today.

I would like to remind everyone that we will be making forward-looking statements during today's webcast. These forward-looking statements include remarks concerning future developments from the pipeline and our company and possible changes in the industry and competitive environment. Because these forward-looking statements involve risks and uncertainties, Galapagos' actual results may differ materially from the results expressed or implied in these statements.

Today's speakers will be Paul Stoffels, CEO; and Bart Filius, COO and President. Paul will reflect on the operational highlights of the year and provide an update on our oncology and immunology franchise. Bart will go over the commercial and financial results.

You will see a presentation on screen. We estimate that the prepared remarks will take about 20 minutes, then we'll open it up to Q&A with Paul and Bart, joined by Michele Manto, Chief Commercial Officer; and Daniele D'Ambrosio, Head of Immunology.

And with that, I'll now turn it over to Paul.

Paul Stoffels

Good morning and good afternoon and welcome to our 2022 annual results reporting. So thank you for joining. It goes without saying that 2022 was an eventful year at Galapagos.

We made significant progress with good sales performance and further rollout of the commercial organization. We entered a new therapeutic area with oncology, with the acquisition of Abound and CellPoint.